An alkaloid initiates phosphodiesterase 3A–schlafen 12 dependent apoptosis without affecting the phosphodiesterase activity

[1]  Lindsay C. Westlake,et al.  Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12 , 2020, The Journal of Biological Chemistry.

[2]  M. Meyerson,et al.  Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing. , 2019, ACS medicinal chemistry letters.

[3]  Xiaodong Wang,et al.  Estrogen-Related Hormones Induce Apoptosis by Stabilizing Schlafen-12 Protein Turnover. , 2019, Molecular cell.

[4]  R. An,et al.  PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth. , 2019, American journal of cancer research.

[5]  G. Baillie,et al.  Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond , 2019, Nature Reviews Drug Discovery.

[6]  C. Erneux,et al.  Potentiation of imatinib by cilostazol in sensitive and resistant gastrointestinal stromal tumor cell lines involves YAP inhibition , 2019, Oncotarget.

[7]  J. Mpindi,et al.  Anagrelide for Gastrointestinal Stromal Tumor , 2018, Clinical Cancer Research.

[8]  H. Woodrow,et al.  : A Review of the , 2018 .

[9]  Xin Wei,et al.  Inhibitors of phosphodiesterase as cancer therapeutics. , 2018, European journal of medicinal chemistry.

[10]  A. Boumendjel,et al.  Traditional uses, phytochemistry and pharmacological properties of African Nauclea species: A review. , 2018, Journal of ethnopharmacology.

[11]  Claes R. Andersson,et al.  Targeting tumor cells based on Phosphodiesterase 3A expression , 2017, Experimental cell research.

[12]  J. Towbin,et al.  Heart Failure in the Child and Young Adult: From Bench to Bedside , 2017 .

[13]  Xiaojun Wang,et al.  Clues for two-step virion infectivity factor regulation by core binding factor beta , 2017, Journal of General Virology.

[14]  Wenqing Gao,et al.  Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin , 2017, Nature.

[15]  V. Manganiello,et al.  Phosphodiesterase 3A: a new player in development of interstitial cells of Cajal and a prospective target in gastrointestinal stromal tumors (GIST) , 2017, Oncotarget.

[16]  A. Napper,et al.  Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient , 2017, Front. Oncol..

[17]  Shuanhu Gao,et al.  Total Synthesis of Camptothecin and Related Natural Products by a Flexible Strategy. , 2016, Angewandte Chemie.

[18]  J. Wolfender,et al.  Nauclea latifolia: biological activity and alkaloid phytochemistry of a West African tree. , 2016, Natural product reports.

[19]  Benito Munoz,et al.  Identification of cancer cytotoxic modulators of PDE3A by predictive chemogenomics , 2015, Nature chemical biology.

[20]  Lei Wang,et al.  Phosphodiesterase 3/4 Inhibitor Zardaverine Exhibits Potent and Selective Antitumor Activity against Hepatocellular Carcinoma Both In Vitro and In Vivo Independently of Phosphodiesterase Inhibition , 2014, PloS one.

[21]  W. Wong,et al.  Subditine, a New Monoterpenoid Indole Alkaloid from Bark of Nauclea subdita (Korth.) Steud. Induces Apoptosis in Human Prostate Cancer Cells , 2014, PloS one.

[22]  M. Mustafa,et al.  Naucline, a New Indole Alkaloid from the Bark of Nauclea officinalis † , 2012, Molecules.

[23]  Jiali Gao,et al.  Insight into the phosphodiesterase mechanism from combined QM/MM free energy simulations , 2011, The FEBS journal.

[24]  J. Corbin,et al.  Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. , 2011, Physiological reviews.

[25]  Daniel L. Popkin,et al.  A Slfn2 mutation causes lymphoid and myeloid immunodeficiency due to loss of immune cell quiescence , 2010, Nature Immunology.

[26]  R. Colman,et al.  New Insights from the Structure-Function Analysis of the Catalytic Region of Human Platelet Phosphodiesterase 3A , 2006, Journal of Biological Chemistry.

[27]  A. Isaksson,et al.  Phenotype-Based Screening of Mechanistically Annotated Compounds in Combination with Gene Expression and Pathway Analysis Identifies Candidate Drug Targets in a Human Squamous Carcinoma Cell Model , 2006, Journal of biomolecular screening.

[28]  V. Manganiello,et al.  Isoforms of Cyclic Nucleotide Phosphodiesterase PDE3 and Their Contribution to cAMP Hydrolytic Activity in Subcellular Fractions of Human Myocardium* , 2005, Journal of Biological Chemistry.

[29]  P. Fossa,et al.  Structural basis for selective PDE 3 inhibition: a docking study , 2002 .

[30]  P. Abreu,et al.  New Indole Alkaloids from Sarcocephalus latifolius , 2001, Natural product letters.

[31]  J. Beavo,et al.  Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. , 1995, Physiological reviews.

[32]  E. Degerman,et al.  Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family). , 1995, Cellular signalling.

[33]  V. Manganiello,et al.  Molecular cloning of the rat adipocyte hormone-sensitive cyclic GMP-inhibited cyclic nucleotide phosphodiesterase. , 1993, The Journal of biological chemistry.

[34]  E. Degerman,et al.  Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[35]  E. Braunwald,et al.  New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 1. , 1986, The New England journal of medicine.

[36]  R. Colman,et al.  Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase. , 1984, Biochemistry.

[37]  M. Movsesian,et al.  Phosphodiesterase inhibition in heart failure. , 2011, Handbook of experimental pharmacology.

[38]  L. Trümper.  From bench to bedside , 2005, Medizinische Klinik.